Management of advanced gastric cancer

Figures & data

Table 1. Selected Phase III trials of first-line chemotherapy in advanced/metastatic gastric cancer.

Study	Treatment	Patients (n)	ORR (%)	1-year OS (%)	Median OS (months)	p-value	Ref.
ML17032	CF CX	137 139	32 46	NA NA	9.3 10.5	NS	[8]
REAL-2	ECF ECX EOF EOX	249 241 235 239	40.7 46.4 42.4 47.9	37.7 40.8 40.4 46.8	9.9 9.9 9.3 11.2	0.02^†	[10]
V325	DCF CF	221 224	37 25	40 32	9.2 8.6	0.02	[16]
ToGA	CX/CF +trastuzumab CX/CF	294 290	47 35	NA NA	13.8 11.1	0.0046	[35]

^†EOX compared with ECF.

CF: Cisplatin, 5-fluorouracil; CX: Cisplatin, capecitabine; DCF: Docetaxel, cisplatin, 5-fluorouracil; ECF: Epirubicin, cisplatin, 5-fluorouracil; ECX: Epirubicin, cisplatin, capecitabine; EOF: Epirubicin, oxaliplatin, 5-fluorouracil; EOX: Epirubicin, oxaliplatin, capecitabine; NA: Not available; NS: Not significant; ORR: Overall response rate; OS: Overall survival.

Table 2. Selected Phase II trials of second-line chemotherapy in advanced/metastatic gastric cancer.

Treatment	Patients (n)	ORR (%)	Median TTP/PFS (months)	Median OS (months)	Ref.
Docetaxel (75 mg/m^2 every 3 weeks)	49	16	2.5	8.3	[63]
FOLFIRI (every 2 weeks)	38	29	3.7	6.4	[60]
Irinotecan (125 mg/m^2 weekly for 4 weeks on a 6-week cycle)	37	20	2.6	5.2	[61]
Irinotecan (160 mg/m^2) plus docetaxel (65 mg/m^2) every 3 weeks	49	20	2.7	8.9	[64]
Paclitaxel (80 mg/m^2 weekly for 3 weeks every 4-week cycle)	38	24	2.1	5	[62]

FOLFIRI: Folinic acid/5-fluorouracil/irinotecan; ORR: Overall/objective response rate; OS: Overall survival; PFS: Progression-free survival; TTP: Time to progression.

Activity Evaluation

Where 1 is strongly disagree and 5 is strongly agree
	1	2	3	4	5
1. The activity supported the learning objectives.
2. The material was organized clearly for learning to occur.
3. The content learned from this activity will impact my practice.
4. The activity was presented objectively and free of commercial bias.

Crew KD, Neugut AI. Epidemiology of gastric cancer. World J. Gastroenterol.12(3), 354–362 (2006).

 PubMed Web of Science ®Google Scholar

Koizumi W, Narahara H, Hara T et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a Phase 3 trial. Lancet Oncol.9(3), 215–221 (2008).

 PubMed Web of Science ®Google Scholar

Bleiberg H, Sargent DJ. GASTRIC meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer. J. Clin. Oncol.29 (2011) (Abstract 4109).

 Google Scholar

Asakura H, Hashimoto T, Harada H et al. Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate? J. Cancer Res. Clin. Oncol.137(1), 125–130 (2011).

 PubMed Web of Science ®Google Scholar

Lee JL, Ryu MH, Chang HM et al. A Phase 2 study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother. Pharmacol.61(4), 631–637 (2008).

 Google Scholar

Assersohn L, Brown G, Cunningham D et al. Phase 2 study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann. Oncol.15(1), 64–69 (2004).

 PubMed Web of Science ®Google Scholar

Chun JH, Kim HK, Lee JS et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn. J. Clin. Oncol.34(1), 8–13 (2004).

 PubMed Web of Science ®Google Scholar

Sym SJ, Chang HM, Kang HJ et al. A Phase 2 study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer Chemother. Pharmacol.63(1), 1–8 (2008).

 PubMed Web of Science ®Google Scholar

Hironaka S, Zenda S, Boku N et al. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer9(1), 14–18 (2006).

 PubMedGoogle Scholar